Sodium-Glucose Transporter 2 Inhibitors: New Therapeutic Targets, New Therapeutic Options in the Treatment of Type 2 Diabetes Mellitus CME

Author Information and Disclosures

Release Date: March 31, 2008; Valid for credit through March 31, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
BMS, AstraZeneca
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review the pathophysiology of type 2 diabetes in the context of the need for new drugs in the armamentarium for glycemic control
  2. Review the role of the kidney in maintaining normal glucose homeostasis
  3. Examine the potential of SGLT2 inhibition in the treatment of type 2 diabetes
Authors and Disclosures

John P.H. Wilding, DM, FRCP
Disclosure: John P.H. Wilding, DM, FRCP, has disclosed that he has served as an advisor or consultant to AstraZeneca, Bristol-Myers Squibb, and GlaxoSmithKline. Dr. Wilding has also disclosed that he has received grants for clinical research from AstraZeneca and Bristol-Myers Squibb.


Dick De Zeeuw, MD, PhD
Disclosure: Dick De Zeeuw, MD, PhD, has disclosed that he has received grants for clinical research from AstraZeneca.


Kristin M. Richardson
Disclosure: Kristin M. Richardson has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.